Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:3302-3309
Published online before print June 13, 2005, doi: 10.1161/CIRCULATIONAHA.104.476242
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
111/24/3302    most recent
CIRCULATIONAHA.104.476242v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arakawa, H.
Right arrow Articles by Ueno, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arakawa, H.
Right arrow Articles by Ueno, H.
Related Collections
Right arrow Animal models of human disease
Right arrow Pathophysiology
Right arrow Arterial thrombosis
Right arrow Other anticoagulants
Right arrow Gene therapy
Right arrow Lipid and lipoprotein metabolism
Right arrow Mechanism of atherosclerosis/growth factors

(Circulation. 2005;111:3302-3309.)
© 2005 American Heart Association, Inc.


Vascular Medicine

Local Expression of Platelet-Activating Factor-Acetylhydrolase Reduces Accumulation of Oxidized Lipoproteins and Inhibits Inflammation, Shear Stress-Induced Thrombosis, and Neointima Formation in Balloon-Injured Carotid Arteries in Nonhyperlipidemic Rabbits

Hideki Arakawa, MD*; Jian-Yong Qian, MD, PhD*; Dolgor Baatar, MD, PhD*; Ken Karasawa, PhD; Yujiro Asada, MD, PhD; Yasuyuki Sasaguri, MD, PhD; Elizabeth R. Miller, BS; Joseph L. Witztum, MD; Hikaru Ueno, MD, PhD

From the Departments of Biochemistry and Molecular Pathophysiology (H.A., J.Q., D.B., H.U.) and Pathology (Y.S.), University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan; Faculty of Pharmaceutical Science, Teikyo University, Kanagawa, Japan (K.K.); Department of Pathology, Miyazaki Medical College, Miyazaki, Japan (Y.A.); and Department of Medicine, University of California at San Diego, La Jolla (E.R.M., J.L.W.).

Correspondence to Hikaru Ueno, MD, PhD, Department of Biochemistry and Molecular Pathophysiology, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, 807-8555 Japan. E-mail hueno{at}med.uoeh-u.ac.jp

Received November 15, 2003; de novo received May 17, 2004; revision received January 20, 2005; accepted March 11, 2005.

Background— Platelet-activating factor (PAF) and PAF-like phospholipids are inactivated by PAF-acetylhydrolase (PAF-AH). Using nonhyperlipidemic animals, we tested whether local expression of PAF-AH into injured arteries might induce antithrombotic and antiinflammatory effects.

Method and Results— Balloon-injured rabbit carotid arteries were infected at the time of injury with an adenovirus expressing either human plasma PAF-AH (AdPAF-AH) or bacterial ß-galactosidase (AdLacZ) or infused with saline. Seven days later, shear stress-induced thrombosis was observed in all AdLacZ-infected and saline-infused arteries (controls) but eliminated in AdPAF-AH-treated contralateral arteries, even in the presence of epinephrine or an inhibitor of NO production. Injury-induced expression of tissue factor was also significantly suppressed. In AdPAF-AH-treated arteries compared with controls, the expressions of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 and macrophage infiltration were decreased by 66%, 66%, and 71%, respectively (P<0.01), and intimal area and intima/media ratio were decreased on day 21 by 43% and 52%, respectively (P<0.05). Within 1 week after injury, oxidized lipoproteins (OxLDL) had readily accumulated in the arterial wall. However, this was markedly reduced in the AdPAF-AH-treated arteries. No differences in the titers of autoantibodies to OxLDL or total cholesterol in blood were found between controls and AdPAF-AH-treated rabbits.

Conclusions— Our results show for the first time that OxLDL accumulates in arteries in nonhyperlipidemic animals within 1 week after injury and that local expression of PAF-AH reduces this accumulation and exerts antiinflammatory, antithrombotic, and antiproliferative effects without changing the plasma levels of PAF-AH activity or titers of autoantibodies to OxLDL.


Key Words: gene therapy • inflammation • lipoproteins • thrombosis • platelet activating factor




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. De Keyzer, S.-A. Karabina, W. Wei, B. Geeraert, D. Stengel, J. Marsillach, J. Camps, P. Holvoet, and E. Ninio
Increased PAFAH and Oxidized Lipids Are Associated With Inflammation and Atherosclerosis in Hypercholesterolemic Pigs
Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2041 - 2046.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
E. J. Welch, R. P. Naikawadi, Z. Li, P. Lin, S. Ishii, T. Shimizu, C. Tiruppathi, X. Du, P. V. Subbaiah, and R. D. Ye
Opposing Effects of Platelet-Activating Factor and Lyso-Platelet-Activating Factor on Neutrophil and Platelet Activation
Mol. Pharmacol., January 1, 2009; 75(1): 227 - 234.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A.-L. Levonen, E. Vahakangas, J. K. Koponen, and S. Yla-Herttuala
Antioxidant Gene Therapy for Cardiovascular Disease: Current Status and Future Perspectives
Circulation, April 22, 2008; 117(16): 2142 - 2150.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A.-L. Levonen, M. Inkala, T. Heikura, S. Jauhiainen, H.-K. Jyrkkanen, E. Kansanen, K. Maatta, E. Romppanen, P. Turunen, J. Rutanen, et al.
Nrf2 Gene Transfer Induces Antioxidant Enzymes and Suppresses Smooth Muscle Cell Growth In Vitro and Reduces Oxidative Stress in Rabbit Aorta In Vivo
Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 741 - 747.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. Kontush and M. J. Chapman
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. M. Stafforini, J. R. Sheller, T. S. Blackwell, A. Sapirstein, F. E. Yull, T. M. McIntyre, J. V. Bonventre, S. M. Prescott, and L. J. Roberts II
Release of Free F2-isoprostanes from Esterified Phospholipids Is Catalyzed by Intracellular and Plasma Platelet-activating Factor Acetylhydrolases
J. Biol. Chem., February 24, 2006; 281(8): 4616 - 4623.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. L. Rufail, H. A. Schenkein, S. E. Barbour, J. G. Tew, and R. van Antwerpen
Altered lipoprotein subclass distribution and PAF-AH activity in subjects with generalized aggressive periodontitis
J. Lipid Res., December 1, 2005; 46(12): 2752 - 2760.
[Abstract] [Full Text] [PDF]